Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.
2.

Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms.

Cardo LF, Coto E, de Mena L, Ribacoba R, Mata IF, Menéndez M, Moris G, Alvarez V.

Neurosci Lett. 2014 Mar 6;562:45-9. doi: 10.1016/j.neulet.2014.01.009. Epub 2014 Jan 10.

PMID:
24418406
3.

rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.

Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C, Baekelandt V.

Mol Neurodegener. 2013 Nov 25;8:44. doi: 10.1186/1750-1326-8-44.

4.

Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.

Taylor TN, Potgieter D, Anwar S, Senior SL, Janezic S, Threlfell S, Ryan B, Parkkinen L, Deltheil T, Cioroch M, Livieratos A, Oliver PL, Jennings KA, Davies KE, Ansorge O, Bannerman DM, Cragg SJ, Wade-Martins R.

Neurobiol Dis. 2014 Feb;62:193-207. doi: 10.1016/j.nbd.2013.10.005. Epub 2013 Oct 10.

5.

Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.

Chiba-Falek O, Lopez GJ, Nussbaum RL.

Mov Disord. 2006 Oct;21(10):1703-8.

PMID:
16795004
6.

Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.

Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, Bernard DJ, El-Agnaf OM, Schlossmacher MG, Nussbaum RL, Chiba-Falek O.

Hum Mol Genet. 2009 Sep 1;18(17):3274-85. doi: 10.1093/hmg/ddp265. Epub 2009 Jun 4.

7.

Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.

Gründemann J, Schlaudraff F, Haeckel O, Liss B.

Nucleic Acids Res. 2008 Apr;36(7):e38. doi: 10.1093/nar/gkn084. Epub 2008 Mar 10.

8.

In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.

Lobb CJ, Zaheer AK, Smith Y, Jaeger D.

J Neurophysiol. 2013 Dec;110(12):2792-805. doi: 10.1152/jn.00441.2013. Epub 2013 Sep 25.

9.

Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.

Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T.

FASEB J. 2008 May;22(5):1327-34. Epub 2007 Dec 27.

10.

A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP.

Kurz A, May C, Schmidt O, Müller T, Stephan C, Meyer HE, Gispert S, Auburger G, Marcus K.

J Neural Transm (Vienna). 2012 Mar;119(3):297-312. doi: 10.1007/s00702-011-0717-3. Epub 2011 Sep 30.

11.

Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.

Miller RM, Kiser GL, Kaysser-Kranich T, Casaceli C, Colla E, Lee MK, Palaniappan C, Federoff HJ.

Exp Neurol. 2007 Mar;204(1):421-32. Epub 2007 Jan 24.

PMID:
17254569
12.

Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.

St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ.

J Neurochem. 2007 Mar;100(6):1449-57. Epub 2007 Jan 4.

13.

The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.

Michell AW, Tofaris GK, Gossage H, Tyers P, Spillantini MG, Barker RA.

Cell Transplant. 2007;16(5):461-74.

PMID:
17708336
14.

Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.

Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Wada K, Hattori N, Mizuno Y, Mochizuki H.

J Neurochem. 2009 Feb;108(4):932-44. doi: 10.1111/j.1471-4159.2008.05827.x. Epub 2009 Jan 7.

15.

Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.

Linnertz C, Saucier L, Ge D, Cronin KD, Burke JR, Browndyke JN, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O.

PLoS One. 2009 Oct 16;4(10):e7480. doi: 10.1371/journal.pone.0007480.

16.

Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.

Flierl A, Oliveira LM, Falomir-Lockhart LJ, Mak SK, Hesley J, Soldner F, Arndt-Jovin DJ, Jaenisch R, Langston JW, Jovin TM, Schüle B.

PLoS One. 2014 Nov 12;9(11):e112413. doi: 10.1371/journal.pone.0112413. eCollection 2014.

17.

Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.

Kalivendi SV, Yedlapudi D, Hillard CJ, Kalyanaraman B.

Free Radic Biol Med. 2010 Feb 1;48(3):377-83. doi: 10.1016/j.freeradbiomed.2009.10.045. Epub 2009 Oct 23.

18.

Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.

Jowaed A, Schmitt I, Kaut O, Wüllner U.

J Neurosci. 2010 May 5;30(18):6355-9. doi: 10.1523/JNEUROSCI.6119-09.2010.

19.

The effect of SNCA 3' region on the levels of SNCA-112 splicing variant.

McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O.

Neurogenetics. 2011 Feb;12(1):59-64. doi: 10.1007/s10048-010-0263-4. Epub 2010 Nov 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk